Associated tags: Chronic kidney disease, Aldosterone, CKD, Therapy, Hypertension, Pharmaceutical industry, Patient
Locations: CALIFORNIA, SAN FRANCISCO, BOSTON, NORTH CAROLINA, NEW ORLEANS, LA, UNITED STATES, NEVADA, MASSACHUSETTS, RADNOR, PA, US, NEW YORK CITY, PENNSYLVANIA
Investment,
Glomerular filtration rate,
Safety,
Conference call,
Research,
Heart,
Aldosterone,
Research and development,
Insurance,
Conference,
Administration,
EGFR,
Obesity,
CKD,
Patient,
Pivotal,
SGLT2,
Hypertension,
Therapy,
Chronic kidney disease,
G&A,
Pharmaceutical industry RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.
Key Points:
- ET –
RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.
- General and Administrative (G&A) expenses were $4.6 million for the quarter ended March 31, 2024, compared to $2.6 million for the quarter ended March 31, 2023.
- Total other income, net was $3.9 million for the quarter ended March 31, 2024, compared to $2.3 million for the quarter ended March 31, 2023.
- Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.
Key Points:
- RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.
- Bank of America Securities Health Care Conference:
Research,
American Heart Association,
Administration,
Conference call,
Conference,
Target,
Obesity,
Prevalence,
CKD,
Part,
Patient,
SGLT2,
G&A,
Pivotal,
Insurance,
Investment,
Research and development,
AHA,
Therapy,
EGFR,
Senior management,
Safety,
Chronic kidney disease,
Hypertension,
Leptin,
BMI,
Aldosterone,
Pharmaceutical industry RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the fourth quarter and full year ending December 31, 2023, and provided a corporate update.
Key Points:
- R&D expenses for the quarter ended December 31, 2023 were $23.7 million, compared to $7.8 million for the quarter ended December 31, 2022.
- G&A expenses were $4.0 million for the quarter ended December 31, 2023, compared to $2.2 million for the quarter ended December 31, 2022.
- Total other income, net was $3.3 million for the quarter ended December 31, 2023, compared to $0.9 million for the quarter ended December 31, 2022.
- Net loss was $24.4 million for the quarter ended December 31, 2023, compared to $9.1 million for the quarter ended December 31, 2022.
Retrieved on:
Wednesday, March 13, 2024
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.
Key Points:
- RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.
- Thursday, March 21st @ 8:30 a.m.
- ET
Retrieved on:
Thursday, February 8, 2024
In the PIPE, Mineralys is selling an aggregate of approximately 8.9 million shares of its common stock (or pre-funded warrants in lieu thereof) at a price of $13.50 per share (or $13.499 per pre-funded warrant).
Key Points:
- In the PIPE, Mineralys is selling an aggregate of approximately 8.9 million shares of its common stock (or pre-funded warrants in lieu thereof) at a price of $13.50 per share (or $13.499 per pre-funded warrant).
- The pre-funded warrants will have an exercise price of $0.001 per share of common stock, will be immediately exercisable and will not expire.
- Mineralys expects to use the net proceeds from the PIPE to fund the research and development of lorundrostat, and for working capital and general corporate purposes.
- BofA Securities and Evercore are acting as placement agents to the Company in connection with the PIPE.
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.
Key Points:
- RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.
- Guggenheim Securities 6th Annual Biotechnology Conference:
Retrieved on:
Thursday, January 4, 2024
Seoul National University,
Business,
National university,
Hypertension,
Yale School of Management,
MBA,
License,
Min-ji,
Aldosterone,
Therapy,
Chronic kidney disease,
Business development,
Roche,
Doctor of Philosophy,
Patient,
Corporation,
Harvard Medical School,
Neurology,
Yale school,
CKD Adam Levy will remain in his role as Chief Financial Officer.
Key Points:
- Adam Levy will remain in his role as Chief Financial Officer.
- “With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team.
- She brings a solid track record of generating value for multiple companies by identifying and executing strategic opportunities,” stated Jon Congleton, Chief Executive Officer of Mineralys.
- Prior to joining Mineralys, she held the role of Chief Business Officer at Affamed Therapeutics and General Manager at Affamed Digital, and brought multiple products into their pipeline.
Retrieved on:
Thursday, December 21, 2023
RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment.
Key Points:
- “Initiating this second pivotal trial demonstrates the continued progress we’re making towards introducing a targeted approach to care in hypertension by identifying and profiling potential responders to lorundrostat,” stated Jon Congleton, Chief Executive Officer of Mineralys.
- This trial is designed to model real world treatment of uHTN and rHTN in the primary care setting.
- Previously, in May 2023, the Company announced the first subject dosed in the first pivotal trial, Advance-HTN.
- The Company expects to announce topline data from the Advance-HTN trial in the second half of 2024.
Retrieved on:
Saturday, November 11, 2023
Chronic kidney disease,
Blood pressure,
Hypertension,
Therapy,
AHA,
BP,
Patient,
CKD,
Obesity,
American Heart Association,
Aldosterone,
Leptin,
BMI,
Risk,
Poster,
Target,
Pharmaceutical industry RADNOR, Pa., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today presented data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorundrostat, a highly selective aldosterone synthase inhibitor. The data were presented in a poster at the American Heart Association (AHA) Scientific Sessions 2023, which is being held in Philadelphia from November 11th –13th.
Key Points:
- The data were presented in a poster at the American Heart Association (AHA) Scientific Sessions 2023, which is being held in Philadelphia from November 11th –13th.
- Data previously presented from Target-HTN showed that elevated body mass index (BMI) was predictive of an enhanced reduction in systolic blood pressure (BP) from lorundrostat treatment.
- Target-HTN trial results support the transition to late-stage development of lorundrostat as a treatment for uncontrolled or resistant hypertension.
- The poster at AHA Scientific Sessions 2023 titled, “Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension - An Endotype-Specific, Targeted Approach to the Treatment of Uncontrolled Hypertension,” can be accessed on the publications page of the Mineralys corporate website.
Retrieved on:
Thursday, November 9, 2023
RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference being held in Miami on November 28-30.
Key Points:
- RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference being held in Miami on November 28-30.
